The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphoma
David Bond, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, briefly discusses the promising results of the SWOG S1826 trial (NCT03907488), which is comparing the safety and efficacy of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in patients with advanced stage classical Hodgkin lymphoma (cHL). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
